No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone

The dopamine hypothesis of schizophrenia received strong support when a two- to three-fold elevation of D2 receptor densities was demonstrated by positron emission tomography (PET) and [11C]N-methylspiperone ([11C]NMSP). In the present study, the reproducibility of this finding was examined by application of a similar method in seven normal comparison subjects and seven neuroleptic-naive schizophrenic patients examined by PET before and after administration of haloperidol, 7.5 mg. After haloperidol, the specific binding of [11C]NMSP was reduced by 80-90%, resulting in a signal-to-noise ratio that was unfavorably low for reliable quantification. No significant difference was found between normal subjects and patients in a descriptive analysis of the time-activity curves or in a nonequilibrium graphical determination of D2 receptor densities in the basal ganglia. The results are consistent with those of a previous quantitative PET study of [11C]raclopride binding, which showed normal densities of D2 receptors in the striatum of neuroleptic-naive schizophrenic patients.

[1]  G. Sedvall,et al.  Imaging of neurotransmitter receptors in the living human brain. , 1986, Archives of general psychiatry.

[2]  L L Iversen,et al.  Increased brain dopamine and dopamine receptors in schizophrenia. , 1982, Archives of general psychiatry.

[3]  T. Kuno,et al.  Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics , 1986, Biological Psychiatry.

[4]  C. Bohm,et al.  Automated blood sampling systems for positron emission tomography , 1988 .

[5]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[6]  B. Mazoyer,et al.  The Estimated Density of D2 Striatal Receptors in Schizophrenia , 1991, British Journal of Psychiatry.

[7]  T. Greitz,et al.  Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. , 1981, Journal of computer assisted tomography.

[8]  M. Ticku,et al.  Central cardiovascular effects of baclofen in spontaneously hypertensive rats. , 1987, Life sciences.

[9]  J. Palacios,et al.  Serotonin receptors in the human brain—III. Autoradiographic mapping of serotonin-1 receptors , 1987, Neuroscience.

[10]  M. Kuhar,et al.  In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. , 1987, Life sciences.

[11]  N. Volkow,et al.  Positron emission tomography (PET) studies of dopaminergic/cholinergic interaction in the baboon brain , 1990, Synapse.

[12]  Jonathan M. Links,et al.  Imaging dopamine receptors in the human brain by positron tomography , 1983 .

[13]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[14]  J. Baron,et al.  In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone. , 1985, European journal of pharmacology.

[15]  J M Links,et al.  3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[16]  D. Stanski,et al.  Haloperidol kinetics after oral and intravenous doses , 1983, Clinical pharmacology and therapeutics.

[17]  L. Iversen,et al.  DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS? , 1980, The Lancet.

[18]  Alan A. Wilson,et al.  Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with11C-N-methylspiperone , 1993, Psychiatry Research.

[19]  M. Mintun,et al.  Comparison in animal models of 18F-spiroperidol and 18F-haloperidol: potential agents for imaging the dopamine receptor. , 1983, Life sciences.

[20]  L. Iversen,et al.  Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue. , 1980, Advances in biochemical psychopharmacology.

[21]  L. Farde,et al.  Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  D. Wong.  PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia". , 1992, Neuropsychopharmacology.

[23]  A. Gjedde,et al.  Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  G. Sedvall,et al.  Further studies on the accumulation and disappearance of catecholamines formed from tyrosine-14C in mouse brain. Effect of some phenothiazine analogues. , 1970, European journal of pharmacology.

[25]  M. Raichle,et al.  Preliminary studies with [18F]haloperidol: a radioligand for in vivo studies of the dopamine receptors , 1980, Brain Research.

[26]  M. Folstein,et al.  EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN , 1984, Science.

[27]  G. Sedvall.  The current status of PET scanning with respect to schizophrenia. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[28]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[29]  P Riederer,et al.  Bimodal distribution of dopamine receptor densities in brains of schizophrenics. , 1984, Science.

[30]  M. Kuhar,et al.  Receptors for neurotransmitters and peptide hormones. , 1980, Advances in biochemical psychopharmacology.

[31]  Van Rossum Jm.  The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. , 1966 .

[32]  Y. Agid,et al.  Loss of Striatal [76Br]Bromospiperone Binding Sites Demonstrated by Positron Tomography in Progressive Supranuclear Palsy , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[34]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[35]  J. Links,et al.  Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report. , 1985, Psychopharmacology bulletin.

[36]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.

[37]  G. Pearlson,et al.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.

[38]  S. Holte,et al.  Evaluation of the Karolinska new positron camera system; the Scanditronix PC2048-15B , 1990 .

[39]  A. Wilson,et al.  An improved synthesis of (3-N-[11C]methyl)spiperone. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[40]  M. Larsson,et al.  A high-performance liquid chromatographic method for the determination of haloperidol and reduced haloperidol in serum , 1983 .

[41]  J. Baron,et al.  Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. , 1990, The American journal of psychiatry.

[42]  G. Sedvall,et al.  Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain. , 1968, The Journal of pharmacology and experimental therapeutics.

[43]  J M Links,et al.  Quantification of Neuroreceptors in the Living Human Brain. II. Inhibition Studies of Receptor Density and Affinity , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[44]  S. Stone-Elander,et al.  No D2 receptor increase in PET study of schizophrenia. , 1987, Archives of general psychiatry.

[45]  N. Andreasen,et al.  Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. , 1988, Schizophrenia bulletin.

[46]  C. Halldin,et al.  Ligand metabolites in plasma during PET‐studies with the 11C‐labelled dopamine antagonists, raclopride, SCH 23390 and N‐methylspiroperidol , 1992 .